BioTech 365

MAY 11, 2021

Million Worldwide Recombinant DNA Technology Industry to 2027 – Impact of COVID-19 on the Market – ResearchAndMarkets.com $609.8

Recombinant DNA Technology 40

Recombinant DNA Technology DNA Marketing 40

pharmaphorum

FEBRUARY 22, 2021

Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses to boost the immune system with its jabs. A single shot vaccine from Johnson & Johnson is also being reviewed by the FDA, which could also be approved in Europe in the coming weeks.

Vaccination 89

Vaccination Vaccine Recombinant DNA Technology Trials 89

Pharmaceutical Technology

FEBRUARY 24, 2023

Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Roots Analysis

JANUARY 21, 2024

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

The Pharma Data

JULY 11, 2021

TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is formulated for subcutaneous administration and has a half-life of approximately two weeks in patients with HAE.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

Pharmaceutical Technology

FEBRUARY 15, 2023

110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99